Our core mission is to prevent the progression of heart failure after MI by repairing tissue damage and restoring cardiac function.
A cutting edge therapeutic for modern regenerative medicine.
Regencor is a regenerative medicine company focused on developing cardiac regenerative therapies that target myocardial infarction and heart failure. We have discovered and patented recombinant glycosylation variants of human circulating FSTL1 that are remarkably regenerative after cardiac injury.
Mitigating heart failure after cardiac injury
Through our first in class therapeutics, we aim to facilitate cardiac regeneration and scar tissue reduction after cardiac injury.
Our solutions lead to improved cardiac function and reduced harmful consequences of heart attacks - such as progression to heart failure - resulting in increased patient quality of life.
Myocardial Infarction is the leading cause of cardiac tissue damage & subsequent development of heart failure.
Global incidence of acute myocardial infarction
Of people with a first MI will progress to heart failure within 5 years, even with optimal medical management
Estimated number of heart failure patients worldwide
With no new drugs on the market, MI and post-MI heart failure remain deadly diseases with no curative or preventive treatment options.
9 years of R&D to establish a cutting edge therapeutic for modern regenerative medicine.